Clinical Trial Update: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin [Phase 3]

View source ↗

Summary

Phase 3 study of Cretostimogene in non-muscle invasive bladder cancer unresponsive to BCG; the trial is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cretostimogene (cretostimogene)

Snippet

Sponsor: CG Oncology, Inc. | Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING